FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ATP6V1E1-BID

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ATP6V1E1-BID
FusionPDB ID: 8175
FusionGDB2.0 ID: 8175
HgeneTgene
Gene symbol

ATP6V1E1

BID

Gene ID

529

637

Gene nameATPase H+ transporting V1 subunit E1BH3 interacting domain death agonist
SynonymsARCL2C|ATP6E|ATP6E2|ATP6V1E|P31|Vma4FP497
Cytomap

22q11.21

22q11.21

Type of geneprotein-codingprotein-coding
DescriptionV-type proton ATPase subunit E 1ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1H(+)-transporting two-sector ATPase, 31kDa subunitH+-transporting ATP synthase chain E, vacuolarV-ATPase 31 kDa subunitV-ATPase subunit E 1V-ATPase, subunit EvacBH3-interacting domain death agonistBH3 interacting domain death agonist Si6 isoformBID isoform ES(1b)BID isoform L(2)BID isoform Si6Human BID coding sequenceapoptic death agonistdesmocollin type 4p22 BID
Modification date2020031320200313
UniProtAcc

P36543

Main function of 5'-partner protein: FUNCTION: Subunit of the peripheral V1 complex of vacuolar ATPase essential for assembly or catalytic function. V-ATPase is responsible for acidifying a variety of intracellular compartments in eukaryotic cells.

P55957

Main function of 5'-partner protein: FUNCTION: The major proteolytic product p15 BID allows the release of cytochrome c (By similarity). Isoform 1, isoform 2 and isoform 4 induce ICE-like proteases and apoptosis. Isoform 3 does not induce apoptosis. Counters the protective effect of Bcl-2. {ECO:0000250|UniProtKB:P70444, ECO:0000269|PubMed:14583606}.
Ensembl transtripts involved in fusion geneENST idsENST00000253413, ENST00000399796, 
ENST00000399798, ENST00000478963, 
ENST00000399767, ENST00000399774, 
ENST00000473439, ENST00000342111, 
ENST00000399765, ENST00000551952, 
ENST00000317361, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score7 X 7 X 2=988 X 6 X 7=336
# samples 79
** MAII scorelog2(7/98*10)=-0.485426827170242
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(9/336*10)=-1.90046432644909
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ATP6V1E1 [Title/Abstract] AND BID [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ATP6V1E1 [Title/Abstract] AND BID [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ATP6V1E1(18095578)-BID(18226779), # samples:1
BID(18220783)-ATP6V1E1(18096086), # samples:1
BID(18220782)-ATP6V1E1(18096086), # samples:1
Anticipated loss of major functional domain due to fusion event.ATP6V1E1-BID seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ATP6V1E1-BID seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
BID-ATP6V1E1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
BID-ATP6V1E1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
BID-ATP6V1E1 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
BID-ATP6V1E1 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
BID-ATP6V1E1 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneBID

GO:0001836

release of cytochrome c from mitochondria

17052454

TgeneBID

GO:0031334

positive regulation of protein complex assembly

19074440|21041309

TgeneBID

GO:0090150

establishment of protein localization to membrane

21041309



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr22:18095578/chr22:18226779)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ATP6V1E1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across BID (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000253413ATP6V1E1chr2218095578-ENST00000317361BIDchr2218226779-24754591081034308
ENST00000399796ATP6V1E1chr2218095578-ENST00000317361BIDchr2218226779-240438837963308
ENST00000399798ATP6V1E1chr2218095578-ENST00000317361BIDchr2218226779-234032439899286

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000253413ENST00000317361ATP6V1E1chr2218095578-BIDchr2218226779-0.0018557960.99814427
ENST00000399796ENST00000317361ATP6V1E1chr2218095578-BIDchr2218226779-0.0018455340.99815446
ENST00000399798ENST00000317361ATP6V1E1chr2218095578-BIDchr2218226779-0.0013033330.99869674

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ATP6V1E1-BID

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ATP6V1E1chr2218095578BIDchr221822677932495RLKVLRARDDLITVNNGSSLRDECIT
ATP6V1E1chr2218095578BIDchr2218226779388117RLKVLRARDDLITVNNGSSLRDECIT
ATP6V1E1chr2218095578BIDchr2218226779459117RLKVLRARDDLITVNNGSSLRDECIT

Top

Potential FusionNeoAntigen Information of ATP6V1E1-BID in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ATP6V1E1-BID_18095578_18226779.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-A30:08RARDDLITV0.99570.8472514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-A74:03TVNNGSSLR0.93870.52251221
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-A74:11TVNNGSSLR0.93870.52251221
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-A74:09TVNNGSSLR0.93870.52251221
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-B15:16RARDDLITV0.81720.9187514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-A02:21RARDDLITV0.60010.5698514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-B13:02RARDDLITV0.51840.8527514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-B52:01RARDDLITV0.14230.8744514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-A02:13VLRARDDLITV0.91750.7547314
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C15:04RARDDLITV0.99950.9186514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C15:06RARDDLITV0.99910.9363514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C03:19ITVNNGSSL0.99740.98241120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C03:07ITVNNGSSL0.99730.96381120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C03:08ITVNNGSSL0.99730.89591120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C15:06ITVNNGSSL0.99520.88531120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C12:12ITVNNGSSL0.98670.9481120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C02:06RARDDLITV0.97450.9833514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C12:04RARDDLITV0.96730.9945514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C01:17ITVNNGSSL0.96480.89071120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C03:19RARDDLITV0.95880.9868514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C06:03RARDDLITV0.95540.995514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C03:08RARDDLITV0.9540.9273514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C08:04ITVNNGSSL0.90990.92351120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C08:13ITVNNGSSL0.90990.92351120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C12:12RARDDLITV0.90290.9531514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C01:30ITVNNGSSL0.82210.93131120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C03:14ITVNNGSSL0.79660.95591120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C08:04RARDDLITV0.77630.9805514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C08:13RARDDLITV0.77630.9805514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C02:06ITVNNGSSL0.72530.95791120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C08:03ITVNNGSSL0.64650.96541120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C03:14RARDDLITV0.55170.9774514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C15:09RARDDLITV0.99950.9186514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C15:02RARDDLITV0.99940.9279514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C15:05RARDDLITV0.99920.9456514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C03:04ITVNNGSSL0.99740.98421120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C03:03ITVNNGSSL0.99740.98421120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-A30:01RARDDLITV0.99570.9286514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C03:67ITVNNGSSL0.99550.97191120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C03:05ITVNNGSSL0.99460.90241120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C15:05ITVNNGSSL0.99460.89931120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C03:17ITVNNGSSL0.99350.95151120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C03:02ITVNNGSSL0.99340.94761120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C12:02ITVNNGSSL0.99170.95521120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C16:04ITVNNGSSL0.98820.97761120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C16:02RARDDLITV0.98160.9899514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C03:17RARDDLITV0.96790.9784514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C03:06ITVNNGSSL0.96060.98391120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C03:05RARDDLITV0.95970.9522514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C01:02ITVNNGSSL0.95940.88441120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C02:10RARDDLITV0.95750.9825514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C02:02RARDDLITV0.95750.9825514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C16:04RARDDLITV0.95210.9725514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-A74:01TVNNGSSLR0.93870.52251221
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C01:03ITVNNGSSL0.91790.91611120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C16:01RARDDLITV0.88050.9729514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C12:03RARDDLITV0.85450.9843514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-B07:13RARDDLITV0.84530.8613514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C16:01ITVNNGSSL0.83560.96511120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C17:01RARDDLITV0.80950.9764514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-B15:30ITVNNGSSL0.73150.75271120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-B07:13ITVNNGSSL0.72820.75491120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C12:02RARDDLITV0.68760.9731514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C08:01ITVNNGSSL0.64650.96541120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-A02:06RARDDLITV0.60010.5698514
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-C17:01ITVNNGSSL0.35640.89671120
ATP6V1E1-BIDchr2218095578chr2218226779459HLA-A02:03VLRARDDLITV0.99490.6531314

Top

Potential FusionNeoAntigen Information of ATP6V1E1-BID in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ATP6V1E1-BID_18095578_18226779.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0338DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0403RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0403ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0413RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0413ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0415RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0415ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0427RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0431RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0436RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0436ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0439RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0439ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0440RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0440ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0441RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0441ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0442RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0442ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0444RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0446RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0446ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0449RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0449ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0450RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0450ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0451RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0451ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0452RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0452ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0453RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0453ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0455RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0455ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0456RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0456ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0458RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0458ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0459RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0459ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0460RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0460ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0465RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0468RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0468ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0470RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0470ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0471RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0471ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0473RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0478RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0479RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0479ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0485RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0485ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0488RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-0488ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-1448DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-1448RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-1525DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB1-1525RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0109DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0109RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0201DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0201RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0201DLITVNNGSSLRDEC924
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0201ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0202DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0202RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0204DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0204RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0204DLITVNNGSSLRDEC924
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0204ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0205DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0209DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0209RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0209ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0209DLITVNNGSSLRDEC924
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0210DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0210RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0211DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0212DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0212RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0213DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0213RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0214DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0214RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0214DLITVNNGSSLRDEC924
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0214ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0215DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0215RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0216DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0216RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0217DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0217RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0218DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0218RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0219DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0219RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0220DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0220RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0221DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0221RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0221ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0221DLITVNNGSSLRDEC924
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0222DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0222RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0223DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0223RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0224DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0224RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0224DLITVNNGSSLRDEC924
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0224ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0225DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0225RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0301DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0301RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0301DLITVNNGSSLRDEC924
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0301ARDDLITVNNGSSLR621
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0303DDLITVNNGSSLRDE823
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0303RDDLITVNNGSSLRD722
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0303DLITVNNGSSLRDEC924
ATP6V1E1-BIDchr2218095578chr2218226779459DRB3-0303ARDDLITVNNGSSLR621

Top

Fusion breakpoint peptide structures of ATP6V1E1-BID

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
540ARDDLITVNNGSSLATP6V1E1BIDchr2218095578chr2218226779459

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ATP6V1E1-BID

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN540ARDDLITVNNGSSL-7.9962-8.1096
HLA-B14:023BVN540ARDDLITVNNGSSL-5.70842-6.74372
HLA-B52:013W39540ARDDLITVNNGSSL-6.83737-6.95077
HLA-B52:013W39540ARDDLITVNNGSSL-4.4836-5.5189
HLA-A11:014UQ2540ARDDLITVNNGSSL-10.0067-10.1201
HLA-A11:014UQ2540ARDDLITVNNGSSL-9.03915-10.0745
HLA-A24:025HGA540ARDDLITVNNGSSL-6.56204-6.67544
HLA-A24:025HGA540ARDDLITVNNGSSL-5.42271-6.45801
HLA-B44:053DX8540ARDDLITVNNGSSL-7.85648-8.89178
HLA-B44:053DX8540ARDDLITVNNGSSL-5.3978-5.5112
HLA-A02:016TDR540ARDDLITVNNGSSL-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of ATP6V1E1-BID

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ATP6V1E1-BIDchr2218095578chr22182267791120ITVNNGSSLATCACAGTCAACAACGGTTCCAGCCTC
ATP6V1E1-BIDchr2218095578chr22182267791221TVNNGSSLRACAGTCAACAACGGTTCCAGCCTCAGG
ATP6V1E1-BIDchr2218095578chr2218226779314VLRARDDLITVGTCCTCAGAGCAAGAGATGACCTTATCACAGTC
ATP6V1E1-BIDchr2218095578chr2218226779514RARDDLITVAGAGCAAGAGATGACCTTATCACAGTC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ATP6V1E1-BIDchr2218095578chr2218226779621ARDDLITVNNGSSLRGCAAGAGATGACCTTATCACAGTCAACAACGGTTCCAGCCTCAGG
ATP6V1E1-BIDchr2218095578chr2218226779722RDDLITVNNGSSLRDAGAGATGACCTTATCACAGTCAACAACGGTTCCAGCCTCAGGGAT
ATP6V1E1-BIDchr2218095578chr2218226779823DDLITVNNGSSLRDEGATGACCTTATCACAGTCAACAACGGTTCCAGCCTCAGGGATGAG
ATP6V1E1-BIDchr2218095578chr2218226779924DLITVNNGSSLRDECGACCTTATCACAGTCAACAACGGTTCCAGCCTCAGGGATGAGTGC

Top

Information of the samples that have these potential fusion neoantigens of ATP6V1E1-BID

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
LUADATP6V1E1-BIDchr2218095578ENST00000253413chr2218226779ENST00000317361TCGA-05-4389-01A

Top

Potential target of CAR-T therapy development for ATP6V1E1-BID

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ATP6V1E1-BID

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ATP6V1E1-BID

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource